Select Page

LYNPARZA (olaparib) tablets, for oral use. Initial U.S. Approval: 2014

LYNPARZA (olaparib) tablets, for oral use. Initial U.S. Approval: 2014

LYNPARZA® (olaparib) tablets is a prescription medicine. LYNPARZA® (olaparib) tablets used for Ovarian cancer and Breast cancer treatment.
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
Ovarian cancer
• for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
• for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Breast cancer
• in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
Tablets: 150 mg, 100 mg
Manufactured By: AstraZeneca
Prescribing Information URL: Click Here

Procedure to buy LYNPARZA® (olaparib) tablets?
To buy LYNPARZA® (olaparib) tablets, patients can simply fill the order form or can send mail at or can also send Whatsapp message at +91 96677 50889. You will get reply within few hours with pricing and procedure details. Note:- the order will be confirmed only after the receipt of valid prescription of doctor.

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

In December 2014, olaparib was approved for use as a single agent by the European Medicines Agency (EMA) in the European Union and by the Food and Drug Administration (FDA) in the United States. The FDA approval was for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy. In January 2018, olaparib became the first PARP inhibitor to be approved by the FDA for gBRCAm metastatic breast cancer.

Olaparib was developed and first dosed into patients by the UK-based biotechnology company, KuDOS Pharmaceuticals, that was founded by Stephen Jackson of Cambridge University, UK. Since KuDOS was acquired by AstraZeneca in 2006, the drug has undergone clinical development by AstraZeneca and Merck & Co. Olaparib in combination with temozolomide demonstrated substantial clinical activity in relapsed small cell lung cancer.


  1. Doctor’s Prescription – We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.
  2. Patient’s Medical history – We would require all test reports and medical reports of the patient for last 3 months.
  3. Patient’s Identity card – We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

For Overseas Patient

Can I get anti-cancer medicines even if I am not based in India?

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. The Bionique Healthcare can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find the best price of –

LYNPARZA (olaparib) tablets in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
LYNPARZA (olaparib) tablets in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
LYNPARZA (olaparib) tablets in North America – Mexico.
LYNPARZA (olaparib) tablets in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
LYNPARZA (olaparib) tablets in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
LYNPARZA (olaparib) tablets in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
LYNPARZA (olaparib) tablets in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
LYNPARZA (olaparib) tablets in Australia and New Zealand.

For Indian Patient

Ani-Cancer LYNPARZA (olaparib) tablets are prescription drug. 

We facilitate by-

  • Helping in documentation to import the medicine for personal use.
  • Finding Genuine and reliable source in USA, Europe and Japan.
  • Ensuring 100% transparency.

LYNPARZA (olaparib) tablets can be shipped to Ahmedabad, Bangalore, Chennai, Cochin, Hyderabad, Delhi, Haryana, Jaipur, Jammu and Kashmir, Himachal Pradesh, Kolkata, Lucknow, Mumbai, Pune, Punjab and other cities in India. Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. 


There are no reviews yet.

Be the first to review “LYNPARZA (olaparib) tablets, for oral use. Initial U.S. Approval: 2014”

Your email address will not be published.

Anti-Cancer Medicine Supplier.

Bionique Healthcare is a consulting pharmaceutical company which assist Patients in accessing medicines in India. Bionique Healthcare facilitates such access only against valid prescriptions in conformity with all local laws and regulations.

Patients/ Clinicians / Researchers can contact Bionique at +91 9667750889 or write to at –

Product Disclaimer

Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturer or licensee. 

Bionique Healthcare does not lay any claim on them.